. Author manuscript; available in PMC: 2022 Nov 23.

Published in final edited form as: Clin Gastroenterol Hepatol. 2019 Dec 13;18(8):1842–1850.e6. doi: 10.1016/j.cgh.2019.11.060

Table 2.

CAP Measurement Using the M Probe Is Significantly Lower Compared With the XL Probe

	Overall (N = 100)	MRI-PDFF <5% (n = 32)	MRI-PDFF ≥5% (n = 68)	MRI-PDFF ≥10% (n = 48)
M probe CAP	310 (61.6)	261.5 (60.6)	323.50 (46.5)	333.5 (33.7)
XL probe CAP	317 (63.2)	259.5 (54.6)	340.63 (52.1)	350.0 (35.5)
P value	.007^a	.235	.017^a	.003^a

The P value determined using a paired nonparametric Wilcoxon test.

CAP, controlled attenuation parameter; MRI-PDFF, magnetic resonance imaging–proton density fat fraction.

P value <.05.